Cognition Therapeutics (CGTX)
NASDAQ:CGTX
US Market
Holding CGTX?
Track your performance easily

Cognition Therapeutics (CGTX) Income Statement

176 Followers

Cognition Therapeutics Income Statement

Last quarter (Q2 2024), Cognition Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Cognition Therapeutics's net income was $-14.35M. See Cognition Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 58.71M$ 50.72M$ 43.55M$ -28.60M$ 6.55M$ 4.67M
Operating Income
$ -58.71M$ -50.72M$ -43.55M$ -28.60M$ -6.55M$ -4.67M
Net Non Operating Interest Income Expense
$ -28.00K$ -27.00K$ -28.00K$ 895.00K$ -1.75M$ -1.02M
Other Income Expense
$ 158.00K$ 158.00K$ -35.00K$ -17.86M$ 464.00K$ 849.00K
Pretax Income
$ -43.30M$ -25.79M$ -21.40M$ -11.72M$ -7.84M$ -4.84M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
---$ -2.24M--
Net Income Common Stockholders
$ -38.39M$ -25.79M$ -21.40M$ -16.25M$ -12.07M$ -8.76M
Basic EPS
$ -0.94$ -0.86$ -0.91$ -3.13$ -0.56$ -0.41
Diluted EPS
$ -0.94$ -0.86$ -0.91$ -3.13$ -0.56$ -0.41
Basic Average Shares
$ 135.21M$ 30.03M$ 23.64M$ 5.19M$ 21.37M$ 21.37M
Diluted Average Shares
$ 135.21M$ 30.03M$ 23.64M$ 5.19M$ 21.37M$ 21.37M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 58.71M$ 25.92M$ 21.33M$ -28.60M$ 6.55M$ 4.67M
Net Income From Continuing And Discontinued Operation
$ -31.08M$ -25.79M$ -21.40M$ -11.72M$ -7.84M$ -4.84M
Normalized Income
$ -57.24M$ -40.13M--$ -7.91M$ -4.60M
Interest Expense
----$ 1.75M$ 1.02M
EBIT
$ -35.97M$ -25.76M$ -21.37M$ -13.12M$ -6.09M$ -3.82M
EBITDA
$ -35.72M$ -25.51M$ -21.13M$ -12.65M$ -5.99M$ -3.74M
Currency in USD

Cognition Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis